Regeneron Prescription drugs Inc. (NASDAQ:REGN) is among the 12 Best Widow and Orphan Stocks to Buy According to Analysts.
On September 17, 2025, Regeneron Prescription drugs Inc. (NASDAQ:REGN) reported optimistic outcomes from a number of late-stage trials, highlighting the power of its pipeline past its core ophthalmology franchise. In its Part 2 COURAGE weight problems trial, the mixture of semaglutide and trevogrumab diminished fats mass by as much as 27.1%, in comparison with 15.7% for semaglutide monotherapy, whereas preserving considerably extra lean muscle mass. General weight discount ranged between 9.9% and 13.4% throughout therapy teams within the 599-patient research.
Moreover, Regeneron Prescription drugs Inc. (NASDAQ:REGN) introduced that the monitoring committee really helpful early crossover in its Part 3 Optima trial of garetosmab for fibrodysplasia ossificans progressiva, after exhibiting a 94% discount in new bone lesions versus placebo. The corporate intends to develop Part 3 testing to pediatric sufferers subsequent yr and submit a U.S. regulatory software for garetosmab by the top of 2025.
Regeneron Prescription drugs Inc. (NASDAQ:REGN) is a world pharmaceutical firm that researches, develops, manufactures, and markets therapies for a variety of illnesses, together with its EYLEA injection for extreme retinal issues. It is among the Greatest Widow and Orphan Shares.
Whereas we acknowledge the potential of REGN as an funding, we imagine sure AI shares provide better upside potential and carry much less draw back danger. For those who’re searching for an especially undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring pattern, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Benefit From AI and 14 Best IT Stocks to Buy for the Long Term.
Disclosure: None.
